LESSENGERS Demonstrates 800G QSFP-DD and 400G QSFP112 Optical Transceivers
12.9.2022 13:00:00 EEST | Business Wire | Press release
LESSENGERS Inc. (“LESSENGERS”), an innovative optical interconnect solution provider, announced today, a live demonstration of polymer-wired 800G QSFP-DD and 400G QSFP112 optical transceivers without the use of any lens optics, providing excellent performance and cost-effectiveness, during the ECOC 2022 (Stand 511 and MR31), the largest optical communications exhibition in Europe, on September 19 – 21, at Messe Basel, Switzerland.
Powered by LESSENGERS’s patent direct optical wiring (DOW) technology, the LESSENGERS 800G QSFP-DD and 400G QSFP112 optical transceivers achieve excellent optical signal integrity and best cost-effectiveness. This unique technology enables complete passive alignment with high-precision and -density optical coupling without the use of lens optics, providing the most suitable solutions for high-speed data center applications such as 800G/1.6T optical modules, on-board, near packaged or co-packaged optics.
“LESSENGERS will demonstrate a set of 112G and 56G signaling-based products during the show, ECOC 2022 on September 19 – 21 to support our customers in urgent needs and will be adding products in the upcoming quarters to complete its product portfolio,” said Taeyong Kim, CMO at LESSENGERS.
“LESSENGERS’s current business is focused on multimode-based optical interconnect solutions along with customized optical packaging services, however, we will continue to push forward on single-mode-based applications such as silicon photonics,” added Chongcook Kim, CEO at LESSENGERS. “This successful demonstration of DOW technology-based optical transceiver solutions will bring a new era of data center optical interconnects and the development of these technologies will support future requirements for high performance computing (HPC) and artificial intelligence (AI) solutions.
LESSENGERS’s demonstration will be with:
- 800G QSFP-DD SR8 optical transceiver
- 400G QSFP112 SR4 optical transceiver
- 200G QSFP56 SR4 optical transceiver
- 200G ultra-small sized optical module
About LESSENGERS
LESSENGERS Inc. is an innovative optical interconnect solution provider. Its patent direct optical wiring (DOW) technology enables high-precision and high-density submicrometer scale optical coupling between high-speed photonic devices and various optical waveguides with the best cost-effectiveness. LESSENGERS’s 800G/400G/200G optical transceiver/active optical cable solutions are powered by the high-performance manufacturing-oriented DOW technologies.
Please visit www.lessengers.com for more information.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220912005022/en/
Contact information
LESSENGERS Inc.
Taeyong Kim, Ph.D
Chief Marketing Officer
+82-10-6549-7654
taeyong.kim@lessengers.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ryan Expands UK Business Rates and Property Tax Capabilities with Acquisition of WYM Rating5.2.2026 10:00:00 EET | Press release
Ryan, a leading global tax services and software provider, is pleased to announce the acquisition of Williams Young McKaig Ltd, a specialized commercial property consultancy, and its specialist rating division, WYM Rating, based in Edinburgh. The acquisition establishes Ryan’s property tax and business rates presence in Scotland and expands the Firm’s ability to serve clients with complex commercial property portfolios across the United Kingdom. Founded in 2012 by Richard Williams, Don Young, and Billy McKaig, WYM Rating is recognized for its client-centered approach and deep expertise across commercial property advisory. The consultancy supports landlords, occupiers, and investors through practical, market-informed advice grounded in decades of hands-on experience. WYM Rating’s capabilities span three focus areas, closely aligning with Ryan’s capabilities: Business rates and property tax Commercial property advisory Occupier and lease advisory “WYM Rating brings exactly the kind of sp
Fujirebio and Sysmex Begin Sales Collaboration for Dementia Testing5.2.2026 08:30:00 EET | Press release
Fujirebio Holdings, Inc. (HQ: Minato-ku, Tokyo; President & CEO: Goki Ishikawa; “Fujirebio”), a consolidated subsidiary of H.U. Group Holdings, Inc. (HQ: Minato-ku, Tokyo; Chairman, President and Group CEO: Shigekazu Takeuchi) and Sysmex Corporation (HQ: Kobe, Japan; President: Kaoru Asano, “Sysmex”) have agreed on a sales collaboration for dementia testing. This agreement follows continued discussions based on the Basic Agreement on Business Collaboration in the Field of Immunoassay concluded in October 2023.1 Sysmex will exclusively sell Fujirebio's fully automated Lumipulse® immunoassay systems and dementia-related reagents ("the Products") in regions and countries mutually agreed upon by both companies. Going forward, Fujirebio and Sysmex will collaborate to meet the growing testing needs accompanying the wider adoption of therapeutic drugs and will gradually expand the countries where the Products are sold. Since entering into the Basic Agreement on Business Collaboration in Octob
Invivoscribe ® Launches LeukoStrat ® KMT2A + MRD Assay to Advance High-Sensitivity Leukemia Testing in Clinical Trials and Patient Management Worldwide5.2.2026 07:30:00 EET | Press release
Invivoscribe, a leader in precision medicine and measurable residual disease (MRD) testing, today announced the addition of the LeukoStrat®KMT2A + MRD Assay and Software to its industry-leading oncology portfolio. The assay leverages digital PCR (dPCR) to support both screening and precise longitudinal MRD monitoring for KMT2A rearrangements in acute myeloid leukemia (AML) subjects. This quantitative test is currently available for research use in clinical trials and as a stand-alone kit for purchase by our global customers, and will soon be available as a service in our regional LabPMM® laboratories worldwide. The assay is available to detect key AML-associated KMT2A rearrangements, which account for the vast majority of KMT2A fusion partners in AML1 and those most commonly targeted in menin-inhibitor clinical development programs. Later this year, the assay will be enhanced with four additional KMT2A rearrangements which are frequently found in acute lymphocytic leukemia (ALL), expan
VeriSilicon Enhanced ISP8200-FS Series IP Achieves ASIL B Functional Safety Certification5.2.2026 02:00:00 EET | Press release
VeriSilicon (688521.SH) today announced its latest enhanced versions of Image Signal Processing (ISP) IP ISP8200-FS series, ISP8200-ES and ISP8200L-ES, featuring improved performance and energy efficiency to better support complex automotive camera systems. These enhanced IPs have successfully achieved ISO 26262 ASIL B functional safety certifications issued by TÜV NORD, an international inspection and certification institution, further validating their suitability and reliability for ADAS and autonomous driving applications. The latest enhanced ISP8200-FS series IP can operate at up to 1.2 GHz and support data processing from up to 16 image sensors. It significantly improves the performance of multi-camera scheduling, enabling flexible data-access capabilities and efficient hardware pipeline utilization for automotive camera systems. The enhanced series IP integrates image processing technologies including Color Noise Reduction (CNR) and radial Lens Shading Correction (LSC), and featu
Mainstay Medical Announces Exclusive Coverage of ReActiv8® by Blue Cross Blue Shield of North Dakota4.2.2026 23:30:00 EET | Press release
Mainstay Medical Holdings plc today announced that Blue Cross Blue Shield of North Dakota has established favorable coverage for the company’s ReActiv8 Restorative NeurostimulationTM therapy for the treatment of intractable chronic low back pain. The policy went into effect in January 2026 and specifies that ReActiv8 is the only therapy considered medically necessary by the policy when the conditions for coverage are met. “We are pleased that another Blue Cross Blue Shield payer has joined Anthem in making ReActiv8 available to well-selected patients after reviewing the large body of clinical evidence we have built,”said Jason Hannon, CEO of Mainstay Medical. “Patients with intractable chronic low back pain are desperately seeking durable solutions, and ReActiv8 has proven to be a safe and effective solution through six clinical studies with 633 patients treated and 1,950 patient-years of follow-up, including two multi-center, randomized controlled clinical studies. We look forward to
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom